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The diabetic phenotype is complex, requiring elucidation of key initiating defects. Diabetic myotubes express a primary reduced
tricarboxylic acid (TCA) cycle ﬂux but at present it is unclear in which part of the TCA cycle the defect is localised. In order to
localise the defect we studied ATP production in isolated mitochondria from substrates entering the TCA cycle at various points.
ATP production was measured by luminescence with or without concomitant ATP utilisation by hexokinase in mitochondria
isolatedfrommyotubesestablishedfromeightleanandeighttype2diabeticsubjects.TheATPproductionofinvestigatedsubstrate
combinations was signiﬁcantly reduced in mitochondria isolated from type 2 diabetic subjects compared to lean. However, when
ATP synthesis rates at diﬀerent substrate combinations were normalized to the corresponding individual pyruvate-malate rate,
there was no signiﬁcant diﬀerence between groups. These results show that the primary reduced TCA cycle ﬂux in diabetic
myotubes is not explained by defects in speciﬁc part of the TCA cycle but rather results from a general downregulation of the
TCA cycle.
1.Introduction
Type2diabetes(T2D)isadisordercharacterisedbyimpaired
insulinsecretionfrombetacellsandinsulinresistance(IR)in
peripheral target tissues. Skeletal muscle is a key tissue site
of the IR. Although a number of abnormalities have been
identiﬁed in skeletal muscle from T2D subjects, the exact
molecular mechanisms for IR have not been established.
The diabetic phenotype is complex, requiring elucidation
of key initiating defects. We have previously described that
myotubes established from T2D subjects conserve the dia-
betic phenotype [1]. Diabetic myotubes express an increased
basal glucose oxidation, and incomplete lipid oxidation
while complete lipid oxidation is reduced [2–6]. Recently
we tested the hypothesis whether these alterations could be
explained by a primarily reduced tricarboxylic acid (TCA)
cycle ﬂux and could show that this was reduced [7]a n d
further that inhibition of TCA cycle ﬂux in lean myotubes by
malonate, a competitive inhibitor of the TCA cycle enzyme
succinate dehydrogenase [8], is followed by a decline in
acetate oxidation, complete palmitate oxidation and ATP
levelwhileglucoseoxidationwasunaﬀected,showingthatan
induced defect can force the lean phenotype in the direction
of the diabetic phenotype [7]. A reduced TCA cycle ﬂux
has been shown in both insulin-resistant oﬀspring of T2D
patients [9] and exercising T2D patients in vivo [10]. Thus,
a reduced TCA cycle ﬂux may be responsible for part of
the diabetic phenotype. The question arises in which part
of the TCA cycle the defect is located, that is, whether the
activity of single enzymes or the whole TCA cycle may be
downregulated.
The intermediary metabolism of skeletal muscle in vivo
is highly inﬂuenced by physical activity, ageing, hormonal
status, and ﬁber type composition, rendering it diﬃcult
to determine the contribution of single factors to the
alteration in mitochondrial metabolism. Cultured myotubes
oﬀer a unique model to distinguish between genetic and
environmental factors in the etiology of insulin resistance
and type 2 diabetes and to elucidate the molecular biological
background [1–7, 11–17]. In the present study, we took
advantage of our model of human myotubes to investi-
gate whether substrates entering the TCA cycle at various2 Biochemistry Research International
Table 1: In vivo characteristics.
Control Diabetic
n 88
Age (years) 51 ±14 9 ±2
Weight (kg) 69.7 ±3.4 101.8 ± 5.1
∗
BMI (kg/m2)2 4 .4 ±0.63 4 .0 ±1.4
∗
Fasting plasma glucose (mM) 5.7 ±0.11 0 .1 ±0.8
∗
Fasting serum insulin (pM) 26.5 ±6.99 4 .6 ±10.1
∗
Glucose infusion rate (mg/min) 388.8 ±22.2 100.0 ±11.9
∗
HbA1c (%) 5.5 ±0.17 .7 ±0.5
∗
Data are means ± SE. ∗Signiﬁcantly diﬀerent from the controls (P<0.05).
points are oxidized diﬀerently in isolated mitochondria from
myotubes established from lean and T2D subjects in order
to clarify whether the activity of single enzymes or the entire
TCA cycle may be downregulated.
2.MaterialsandMethods
2.1. Human Study Subjects. Eight lean and eight obese
patients with type 2 diabetes participated in the study. Their
clinical characteristics have been published [11, 12]a n d
are shown in Table 1. All subjects gave written, informed
consent, and the local ethics committee of Funen and Vejle
County approved the study.
2.2. Cell Culture. Cell cultures were established as previously
described [18–20]. In brief, muscle tissue was minced,
washed, and dissociated for 60min by three treatments
with 0.05% trypsin-EDTA. The cells obtained were seeded
for upscaling on ECM-gel-coated dishes after 30min of
preplating. Growth medium contains DMEM supplemented
with 2% FCS, 2% Ultroser G, 50U/mL penicillin, 50μg/mL
streptomycin, and 1.25μg/mL amphotericin B. Cells were
subcultured twice before ﬁnal seeding. At 75% conﬂuence,
the growth medium was replaced by basal medium (DMEM
supplemented with 2% FCS, 50U/mL penicillin, 50μg/mL
streptomycin, 1.25μg/mL amphotericin B, and 25pmol/L
insulin) in order to induce diﬀerentiation. The cells were
cultured in humidiﬁed 5% CO2 atmosphere at 37◦C, and
medium was changed every 2-3 days. Human myotubes
established from each group were used for analysis at day
eight after onset of diﬀerentiation.
2.3. Mitochondria Isolation and Preparation. Mitochondria
were isolated from cultured human myotubes using the
MACS mitochondria isolation kit from Miltenyi Biotech,
Germany [13].
2.4. ATP. The ATP synthesis in isolated mitochondria
was measured by luminescence at baseline and during
ATP utilization by the hexokinase reaction that catalyses
the production of glucose 6-phosphate from glucose and
ATP. The mitochondrial buﬀers contained 300mM sucrose,
10mM KCl, 10mM KH2PO4, 10mM T ris-Base, 0.1mM
EDTA, and 0.035mM ADP supplemented with diﬀerent
substrate combinations. Initially we investigated the follow-
ing combinations: 1mM pyruvate and 1mM malate (PM
buﬀer), 1mM malate and 5mM glutamate (MG buﬀer),
5mM succinate and 10μMr o t e n o n e( S Rb u ﬀer). In a
second line of experiments we extended these with the
following additional substrate combinations: 1mM acetate
1mM malate (AM buﬀer),1mMcitrate1mMmalate(CM
buﬀer), or 1mM/5mM isocitrate 1mM malate (IM buﬀer).
All buﬀers were supplemented by 3U/mL hexokinase and
1mM glucose during conditions of ATP utilization. ATP
production was measured after 0, 5, 10, 15, and 30min,
respectively. ATP was determined by luminescence (ATPlite,
PerkinElmer,Turku,Finland)in96-wellplatesandmeasured
on a Microbeta counter (PerkinElmer, Finland) as previously
described[21].MitochondrialATPproductionwascorrected
for fading of luminescence of the luciferase used in the ATP
assayandnormalizedperμgofmitochondriaproteinandper
minute.
2.5. Mitochondrial Mass. MitoTracker Green Probe (Molec-
ular Probes, Eugene, OR) was used according to the
manufacturer’s instructions. Fluorescence was determined
on a VICTOR plate reader model 1420-050 (PerkinElmer,
Finland) with excitation and emission wavelength of 485 and
535, respectively, as described previously, [22]. Values were
corrected for protein.
2.6. Statistical Analysis. Data in text, tables, and ﬁgures are
given as mean ± SEM. Statistical analyses were performed
with SPSS (version 17.0). ANOVA test was used to assess
signiﬁcant diﬀerences between groups. P ≤ 0.05 was
considered to be signiﬁcant.
3. Results
3.1. Mitochondrial ATP Synthesis. The ATP production in
isolated mitochondria from diabetic myotubes was signiﬁ-
cantly reduced (P<0.05) compared to mitochondria from
lean in the presence of PM, MG, and SR (Figure 1(a)). When
adding hexokinase to isolated mitochondria to simulate ATP
demand, this was overall conserved (P<0.01) and reached
signiﬁcance for PM (P<0.05, Figure 1(b)).
3.2. Substrate Handling. The ATP synthesis in isolated mito-
chondria was measured at additional substrate combina-
tions (acetate-malate (AM), citrate-malate (CM), isocitrate-
malate (IM)). In order to show diﬀerences in substrate
handlingbetweenmitochondriaisolatedfromleanandobese
T2D subjects ATP synthesis rates at diﬀerent substrate com-
binations were normalized to values at PM. Mitochondria
isolated from myotubes established from type 2 diabetic
subjects did not reveal any diﬀerences in substrate handling
for ATP synthesis compared to lean with or without the
presence of hexokinase (P>0.19) (Figures 1(c) and 1(d)).
3.3. Mitochondrial Mass. The mitochondrial mass in myo-
tubes established from lean and obese diabetic subjectsBiochemistry Research International 3
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Figure 1: Rates of ATP synthesis in isolated mitochondria. The ATP synthesis rate was determined in isolated mitochondria of diﬀerentiated
myotubes established from lean (open bars) and type 2 diabetic subjects (black bars). Isolated mitochondria were incubated with various
substrates as indicated, supplemented with/without hexokinase as described in Section 2. (a) shows ATP synthesis in isolated mitochondria
without hexokinase treatment. ∗P<0.05 versus control. (b) shows ATP synthesis in isolated mitochondria with hexokinase treatment.
∗P<0.05 versus control. (c) shows normalised ATP synthesis rates without hexokinase treatment. (d) shows normalised ATP synthesis rates
with hexokinase treatment. Data are means ± SE, n = 8 in each group. acetate (A), citrate (C), isocitrate (I), glutamate (G), malate (M),
pyruvate (P), rotenone (R), and succinate (S).
was measured in order to identify group diﬀerences in
mitochondrial content. We could not detect any signiﬁcant
diﬀerencesinmitochondrialmassbetweengroups(P = 0.86,
Figure 2).
4. Discussion
Pyruvate, acetate, malate, citrate, isocitrate, glutamate, and
succinate enter the TCA cycle at diﬀerent sites before they
are oxidised, creating a transmembrane potential, powering
thephosphorylationofADPtoATP.Theirenergyispredom-
inantly transferred to complex I of the electron transport
chain (ECT) for all substrates except for the combination
succinate-rotenone which preliminary deliver to complex II.
As in our previous studies of ATP production in isolated
mitochondria from diabetic myotubes, the ATP production
was reduced compared to mitochondria from lean [13, 14].
To search for TCA cycle defects in diabetic mitochondria, we
exposed isolated mitochondria for substrates with diﬀerent
TCA cycle entries to locate TCA cycle defects. All entrance
points to the TCA cycle gave similar normalised ATP
synthesis rates in the two groups indicating that there
may not be a major single primary defect present in the
TCA cycle and the reduced TCA cycle ﬂux in diabetic
mitochondria seems to be based on a general TCA cycle
downregulation. Both complex I and II substrates gave the
same results indicating that the defect is either downstream
from complex II, that is, at the sites of cytochrome C
oxidase or ATP synthase, or a general reduction in TCA
cycle ﬂux. Recent evidence from global approaches such
as microarray gene expression analysis has suggested that
the basis for reduced mitochondrial ATP production in
skeletal muscle from T2D could be a functional impair-
ment in oxidative phosphorylation (OXPHOS) [23, 24].
However, transcriptional proﬁling of myotubes established
from T2D subjects did not show evidence of a primary
defect in OXPHOS genes [22] .M o r e o v e r ,w eh a v ep r e v i o u s l y
determined the uncoupled respiration rate in myotubes
established from lean, obese, and T2D subjects and found
no signiﬁcant diﬀerences between groups, suggesting that
the ETC did not express intrinsic defects [12]. Contradicting
a primary major defect in the oxidative phosphorylation
in human myotubes, the basal glucose oxidation decreased
when oxidative phosphorylation was either inhibited by4 Biochemistry Research International
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Figure 2: Mitochondrial mass. Mitochondrial mass was deter-
mined by MitoTracker Green ﬂuorescence in myotubes established
from lean (open bar) and T2D subjects (black bar). Data are means
± SE, n = 8 in each group.
Antimycin A (Complex III inhibitor) or oligomycin (F0-
F1 inhibitor) in myotubes established from lean, obese, and
T2D subjects [6] showing that lean, obese, and diabetic
react in the same manner. However, diabetic myotubes
express an increased basal glucose oxidation during nor-
mophysiological condition and still expressed an increased
basal glucose oxidation compared to lean myotubes, despite
inhibition of the oxidative phosphorylation, indicating that
defects in the oxidative phosphorylation were not the
major mechanism to explain primary changes in diabetic
myotube metabolism [6]. To identify and quantify changes
in protein abundance between human myotubes obtained
from lean, obese, and type 2 diabetic subjects we did a
quantitative proteomic study [15]. Despite a clear diabetic
phenotype in diabetic myotubes, only twelve proteins were
diﬀerentially expressed between the three diﬀerent groups.
Proteins from all major pathways known to be important
in T2D were well characterized including the TCA cycle,
lipid oxidation, oxidative phosphorylation, the glycolytic
pathway, and glycogen metabolism. None of these enzymes
were found to be regulated at the level of protein expression
or degradation, suggesting that above diﬀerences in ATP
synthesis may not be found on the protein expression level.
Taken together, the above data indicates that there are no
intrinsic single defects in the TCA cycle which could explain
the reduced TCA cycle ﬂux in diabetic mitochondria.
A general downregulation of the TCA cycle can be
obtained at the level of posttranslational modiﬁcation
(PTM) of TCA cycle proteins or through changes in
intramyocellular energy-redox state controlling the overall
TCA cycle ﬂux rate. Less is known about mitochondrial
phosphatases and kinases. Studies indicate that cytosolic
kinases may be translocated into the mitochondria that
is, PKA, PKC, or AKT. A recent paper reports that the
activity of mitochondrial aconitase (a TCA cycle enzyme)
in type 1 diabetic rat hearts is regulated by PKCβ2, whose
activity is dependent on the degree of phosphorylation [25].
Augmented phosphorylation of mitochondrial aconitase was
associated with a reduced TCA cycle ﬂux, based on an
increased reverse activity, while the forward reaction was
normal. That PTM could be part of the explanation for
a reduced TCA cycle ﬂux in diabetic mitochondria is
supported by our previous ﬁnding of a 14% reduced citrate
synthase activity in diabetic myotubes [12] which cannot be
explained by changes in protein expression [15]. Additional
phosphoproteomic studies are required to test whether the
impaired TCA cycle ﬂux, in diabetic mitochondria, is based
on posttranscriptional modiﬁcations of TCA cycle enzymes.
Am o r eo v e r a l lr e g u l a t i o no ft h eT C Ac y c l ei nh u m a n
myotubes may be based on the mitochondrial matrix
phosphorylation potential (Pi + ADP/ATP) and the pyridine
nucleotide redox poise and concentration (NADH/NAD+).
Increasing substrate availability is followed by increasing
concentrations of reduction equivalents and ATP which,
through allosteric inhibition, can downregulate the TCA
cycle ﬂux. Previously we determined the energy charge, the
level of ATP, ADP, and AMP in myotubes established from
lean,obese,andobesetype2diabeticsubjectsatnormophys-
iological conditions and could not verify diﬀerences between
groups [26] indicating that the energy state may not account
for diﬀerences in the TCA cycle ﬂux between groups.
Increased oxidative stress has been implicated in the
development of insulin resistance in type 2 diabetes by both
indirect and direct evidence based on increased damage of
DNA,lipids,andproteins[27].Recentlywemeasuredhydro-
gen peroxide production/mitochondrial mass and found it
signiﬁcantly reduced in diabetic myotubes compared to lean
controls indicating that an increased ROS production may
not be the main mechanism accounting for a reduced TCA
ﬂux in diabetic mitochondria [16].
The reduced but similar ATP production on diﬀer-
ent substrates in diabetic mitochondria could point to
reduced substrate availability as explanation for obtained
diﬀerences, that is, based on impaired transport/interchange
of substrates across the inner mitochondrial membrane.
Several substrates were used in the present study requiring
diﬀerent transporters indicating that transport/interchange
ofsubstrateandintermediatescouldbegenerallyimpairedin
diabetic mitochondria. However, we have recently described
that the inner mitochondrial membrane potential was
conserved in diabetic mitochondria [16]. Further studies are
required to clarify whether substrate availability may be part
of the responsible mechanism for a reduced ATP production
in diabetic mitochondria.
An overall reduced TCA ﬂux in diabetic myotubes
compared to lean myotubes could be based on a reduced
mitochondrial mass in diabetic myotubes. We addressed the
question by measuring the mitochondrial mass in myotubes
established from lean and type 2 diabetic subjects and could
not show signiﬁcant diﬀerences between groups.
In summary, we tested the hypothesis that the reduced
TCA cycle ﬂux in diabetic mitochondria was based on site-
speciﬁc TCA cycle defects but we could not ﬁnd evidence
for this. The primary reduced TCA cycle ﬂux in diabeticBiochemistry Research International 5
myotubes is explained by a general downregulation of the
TCA cycle. We hypothesize that the impaired TCA cycle ﬂux,
in diabetic mitochondria, is based on posttranscriptional
modiﬁcations of TCA cycle enzymes.
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